Category: Hyperhidrosis

Posted on

Global research trends and hotspots of hyperhidrosis: a bibliometric analysis (2008-2023)

Front Surg. 2025 Apr 22;12:1559951. doi: 10.3389/fsurg.2025.1559951. eCollection 2025.

ABSTRACT

BACKGROUND: Recent studies have demonstrated significant advancements in the treatment of hyperhidrosis. However, a bibliometric analysis of relevant studies in this field is notably lacking. This study aims to provide a detailed analysis of research trends and key areas of interest in hyperhidrosis over the last 16 years using bibliometric methods.

METHODS: We searched the Web of Science Core Collection (WoSCC) database for hyperhidrosis-related publications from 2008 to 2023 and conducted bibliometric analysis using VOS viewer and the R package “bibliometrix.”

RESULTS: The main research institutions involved in this study are the University of São Paulo, Hospital Israelita Albert Einstein, Yonsei University and Fujian Medical University, with a total of 728 articles included from 52 countries. Authors from these institutions have published in top journals, with Dermatologic Surgery being the most popular journal and the Journal of the American Academy of Dermatology being the most cited. A total of 2,830 authors have contributed to this field, with prominent researchers including Nelson Wolosker, Paulo Kauffman, Pedro Puech-Leão, Jose Ribas Milanez de Campos, and Dee Anna Glaser. Nelson Wolosker stands out as the most co-cited author. The primary focus of research in this area is on the treatment of hyperhidrosis and the prevention of post-operative complications. Emerging re-search hotspots include keywords such as “botulinum toxin,” “oxybutynin,” “sympathectomy,” “iontophoresis,” and “compensatory sweating”.

CONCLUSION: The most prevalent academic emphasis within this field remains the treatment of hyperhidrosis and the management of compensatory hyperhidrosis. Despite this academic preponderance, there is a compelling necessity to foster enhanced collaboration and exchange between disparate countries and institutions.

PMID:40330089 | PMC:PMC12052815 | DOI:10.3389/fsurg.2025.1559951

Posted on

Case Report: Single-port thoracoscopic surgery for severe primary palmar hyperhidrosis in a 9-year-old child

Front Med (Lausanne). 2025 Apr 15;12:1542064. doi: 10.3389/fmed.2025.1542064. eCollection 2025.

ABSTRACT

Primary palmar hyperhidrosis (PPH) is a somatic condition characterized by excessive sweating of the hands. It mainly affects adolescents and young adults and is rarely observed among children. This condition significantly impairs patients’ academic performance, daily activities, and social interactions and can even lead to insurmountable psychological burdens. Surgical intervention for PPH is typically reserved for individuals aged 16 years and older, as compensatory hyperhidrosis occurs at a high rate (65%) postoperatively among children younger than 14 years. Therefore, the decision for surgery is controversial and has been rarely documented in the literature. Here, we report a 9-year-old child with a 3-year history of bilateral palmar hyperhidrosis. Conservative treatment with medications for 6 months led to no improvement. The patient had signs of low self-esteem, social withdrawal, and aversion to school, alongside recurrent skin damage at the fingertips. Both the child and parents expressed a strong desire for effective treatment. Single-port endoscopic thoracic sympathectomy (ETS) was conducted after comprehensive risk disclosure and obtaining informed consent from the parents, achieving remarkable therapeutic outcomes. At the 12-month follow-up, the patient exhibited no recurrence of symptoms, no compensatory hyperhidrosis, and no complications, such as Horner’s syndrome. Both hands remained warm and dry, the lesions of fingertip skin healed, and the patient’s personality became noticeably more positive. Furthermore, the surgical incision was aesthetically pleasing.

PMID:40303365 | PMC:PMC12037579 | DOI:10.3389/fmed.2025.1542064

Posted on

Investigation and analysis of personality characteristics of primary palmar hyperhidrosis patients: a cross-sectional observational study

Eur J Med Res. 2025 Apr 23;30(1):323. doi: 10.1186/s40001-025-02575-7.

ABSTRACT

BACKGROUND: Patients with primary palmar hyperhidrosis (PPH) may exhibit distinct personality traits that influence their perception of the condition. These traits can manifest as heightened sensitivity to physical symptoms, as well as feelings of anxiety or depression, especially in social settings.

METHODS: This study is a retrospective cross-sectional observational study aimed to evaluate and analyze the personality characteristics of patients with primary palmar hyperhidrosis using the Personality Diagnostic Questionnaire-Version 4 (PDQ-4). This study explored the relationships between personality traits and various factors, including age, gender, body mass index (BMI), onset age, the age when symptoms began to impact daily life (Impact age), the choice of thoracic sympathectomy nerve segment, and postoperative satisfaction. The study enrolled primary palmar hyperhidrosis patients treated at the Thoracic Surgery Department of Beijing Haidian Hospital between 2016 and 2021, with a total of 791 patients meeting the inclusion criteria. Statistical analyses, such as the Chi-square test and Mann-Whitney U-test, were conducted using SPSS 26.0 to investigate associations between personality traits and various variables.

RESULTS: Primary palmar hyperhidrosis patients exhibited a higher prevalence of personality disorders at 16.18% compared to the general population, which ranges from 6.1 to 9.5%. Male patients exhibited a statistically significantly higher prevalence of schizoid, narcissistic, and antisocial personality disorders compared to female patients (P < 0.05). Furthermore, postoperative satisfaction among patients with primary palmar hyperhidrosis declined over time, with a statistically significant difference (P < 0.05). Notably, primary palmar hyperhidrosis patient comorbid personality disorders experienced a more pronounced decline in satisfaction.

CONCLUSIONS: Patients with primary palmar hyperhidrosis demonstrate a relatively high prevalence of personality disorders.

PMID:40269968 | DOI:10.1186/s40001-025-02575-7

Posted on

The comparative study of letibotulinum toxin A and onabotulinum toxin A in treatment of primary axillary hyperhidrosis

Arch Dermatol Res. 2025 Apr 1;317(1):661. doi: 10.1007/s00403-025-04069-2.

ABSTRACT

Primary axillary hyperhidrosis (PAH) is a challenging condition characterized by excessive underarm sweating. The U.S. Food and Drug Administration has approved onabotulinum toxin A (OnaBTX-A, Botox®, Allergan Inc, USA) as the only botulinum toxin treatment for severe axillary hyperhidrosis, and it has demonstrated positive results. Recently, the off-label use of letibotulinum toxin A (LetiBTX-A, Hugel®, Hugel Inc, Korea) has risen significantly for cosmetic purposes due to its effectiveness. For the treatment of primary axillary hyperhidrosis, the authors proposed that LetiBTX-A is at least as effective as OnaBTX-A. To evaluate the efficacy and safety of letibotulinum toxin A (LetiBTX-A) in comparison to onabotulinum toxin A (OnaBTX-A) for treating primary axillary hyperhidrosis (PAH). All participants with a diagnosis of moderate to severe primary axillary hyperhidrosis (Hyperhidrosis Disease Severity Scale (HDSS) score ≥ 2) received random injections of 50 U of LetiBTX-A in one armpit and 50 U of OnaBTX-A in the other site. HDSS score and hyperhidrosis area were measured by using the Minor’s iodine starch test. Participant satisfaction was evaluated at 1, 3, and 6 months following the injection. Onset of action and adverse events were also assessed. All 30 participants completed the study protocol, with the mean age was 34.44 ± 7.82 years and most of the participants were female. The mean age at onset was 20.47 ± 3.01 years and more than 50% of participants had a HDSS score of 3. There was no statistically significant difference observed in the reduction of HDSS scores, hyperhidrosis area, and participant satisfaction between the axillae treated with LetiBTX-A and those treated with OnaBTX-A at 1, 3 and 6 months after injections. The median onset of action of both LetiBTX-A and OnaBTX-A were 2 ± 1 day (p = 0.317). Procedure-related pain was comparable between 2 formulations (P = 0.876). No serious adverse event was observed. This study concluded that LetiBTX-A and OnaBTX-A demonstrate comparable efficacy and safety profiles in treating primary axillary hyperhidrosis (PAH).

PMID:40167830 | DOI:10.1007/s00403-025-04069-2

Posted on

Effectiveness of Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis Who Experienced Residual or Recurrence of Axillary Odor after Surgery for Axillary Osmidrosis

J Plast Reconstr Surg. 2024 Jul 5;4(1):13-19. doi: 10.53045/jprs.2023-0067. eCollection 2025 Jan 27.

ABSTRACT

OBJECTIVES: Sofpironium bromide is the first topical anticholinergic drug approved in Japan for the treatment of primary axillary hyperhidrosis. This study aimed to investigate the effectiveness of sofpironium bromide in patients with primary axillary hyperhidrosis who experienced residual axillary odor or recurrence of axillary odor after surgery with subdermal excision of apocrine glands by skin flap procedure for axillary osmidrosis.

METHODS: A total of 56 patients who underwent surgery for axillary osmidrosis at our hospital between January 2022 and April 2023 were included in this study. Axillary odor and sweat volume were evaluated with patient-reported visual analog scale in 56 patients who underwent surgery for axillary osmidrosis and 13 patients administered with sofpironium bromide after the surgery.

RESULTS: Surgery in patients with axillary osmidrosis significantly improved axillary odor and excessive sweating by approximately 90% and approximately 54%, respectively. Treatment with sofpironium bromide in patients with axillary hyperhidrosis after the surgery significantly improved axillary odor and excessive sweating by approximately 70% and approximately 63%, respectively.

CONCLUSIONS: These results suggest that sofpironium bromide is effective in patients with axillary hyperhidrosis after the surgery. Since this study was conducted with a small number of patients in a retrospective single-arm design, it is necessary to validate the results in a prospective controlled study with a large number of patients.

PMID:40160959 | PMC:PMC11950559 | DOI:10.53045/jprs.2023-0067

Posted on

Which patients are more likely to experience compensatory hyperhidrosis after endoscopic thoracic sympathectomy: a meta-analysis and systematic review

PeerJ. 2025 Mar 18;13:e19097. doi: 10.7717/peerj.19097. eCollection 2025.

ABSTRACT

BACKGROUND: Compensatory hyperhidrosis (CH) is a common consequence of sympathectomy, which can adversely affect patients’ quality of life after surgery. Understanding the factors that influence the occurrence of CH and severe compensatory hyperhidrosis (SCH) is crucial for effective management and counseling of patients undergoing this procedure.

MATERIALS AND METHODS: We registered the protocol in International Prospective Register of Systematic Reviews (CRD42024592389) and following PRISMA guidelines. We searched PubMed, EMBASE, and Web of Science databases for studies published up to September 11, 2024. A systematic literature search identified a total of 10 studies involving 3,117 patients. The primary outcome was the number of CH or SCH. The secondary outcome was the weighted mean difference calculated based on identified related factors. When pooling results or conducting a meta-analysis was not feasible, the study findings were presented in a narrative descriptive format.

RESULTS: The overall incidence of CH was found to be 0.62 (95% confidence interval CI [0.51-0.72]), and four studies totaling 1,618 patients regarding the occurrence of severe compensatory hyperhidrosis, the overall incidence of CH was found to be 0.23 (95% CI [0.12-0.34]). Older age, higher body mass index (BMI) and smoking history correlated positively with CH incidence. In addition, higher BMI level is also associated with the occurrence of SCH (1.20 95% CI [1.01-1.39], p < 0.0001).

CONCLUSION: The findings of this meta-analysis highlight important demographic and lifestyle factors that contribute to the development of CH and SCH following sympathectomy. Older patients, smokers, and those with higher BMI may be at greater risk for these conditions.

PMID:40124609 | PMC:PMC11927556 | DOI:10.7717/peerj.19097